GlassScriptPhysician profile
Amandeep Singh
NPI 1184908295
$1,252.63
in general payments reported to CMS, 2019-2025
14 companies · $911 in 2025
The $911 reported for 2025 was more than what 76% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22.16 · 2023: $103 · 2024: $217 · 2025: $911.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.86 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akebia Therapeutics INC | $317.56 | 2024-2025 | Vafseo |
| Bayer Healthcare Pharmaceuticals INC. | $308.60 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $129.09 | 2023-2025 | Lokelma, Farxiga |
| Otsuka America Pharmaceutical, INC. | $113.91 | 2024-2025 | Jynarque |
| Mallinckrodt Hospital Products INC. | $95.93 | 2025 | Acthar |
| Outset Medical INC | $58.57 | 2025 | |
| Ardelyx, INC. | $55.60 | 2025 | Ibsrela |
| Vifor Pharma, INC. | $45.92 | 2024-2025 | Veltassa |
| Regeneron Healthcare Solutions, INC. | $33.15 | 2024 | Dupixent |
| Abbvie INC. | $22.16 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.54 | 2025 | Jardiance |
| Fresenius USA Marketing, INC. | $19.24 | 2024 | Velphoro |
| Merck Sharp & Dohme LLC | $19.10 | 2025 | Prevymis |
| Amgen INC. | $14.26 | 2025 | Tavneos |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amandeep Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.